Tank1967 wrote: We haven’t seen any severe data
Post# of 148179
(Total Views: 546)
Posted On: 03/05/2021 9:29:34 PM
Tank1967 wrote:
We haven’t seen any severe data at all. 62 patients out of 384 progressed to critical stage. LL saved 24% of the 62. That bodes well for how well LL did in the severe subset of patients.
my response:
To say 62 patients out of 384 progressed to critical stage is not clear.
I would think that the definition of a severe patient, is one who was severe at the time they were injected with leronlimab. I would think that LL saved 24% of the patients who were critical at the time they were injected with LL.
So there were 62 patients who had progressed to critical before they were injected with LL, they were critical when they entered the trial.
Patients who were severe, but got SOC, were more likely to progress to critical, and thus were more likely to die vs those given LL.
We haven’t seen any severe data at all. 62 patients out of 384 progressed to critical stage. LL saved 24% of the 62. That bodes well for how well LL did in the severe subset of patients.
my response:
To say 62 patients out of 384 progressed to critical stage is not clear.
I would think that the definition of a severe patient, is one who was severe at the time they were injected with leronlimab. I would think that LL saved 24% of the patients who were critical at the time they were injected with LL.
So there were 62 patients who had progressed to critical before they were injected with LL, they were critical when they entered the trial.
Patients who were severe, but got SOC, were more likely to progress to critical, and thus were more likely to die vs those given LL.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼